Equities analysts expect that Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) will post earnings of ($0.15) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Achillion Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.15) and the lowest estimate coming in at ($0.16). Achillion Pharmaceuticals reported earnings per share of ($0.03) in the same quarter last year, which would suggest a negative year over year growth rate of 400%. The firm is scheduled to issue its next earnings report on Thursday, February 22nd.
According to Zacks, analysts expect that Achillion Pharmaceuticals will report full-year earnings of ($0.63) per share for the current fiscal year, with EPS estimates ranging from ($0.69) to ($0.60). For the next year, analysts anticipate that the company will report earnings of ($0.67) per share, with EPS estimates ranging from ($0.79) to ($0.55). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Achillion Pharmaceuticals.
Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.04. During the same quarter in the previous year, the firm posted ($0.15) earnings per share.
A number of research firms have recently commented on ACHN. BidaskClub upgraded shares of Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 16th. Robert W. Baird cut shares of Achillion Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 price target on the stock. in a report on Thursday, August 10th. Maxim Group set a $7.00 price target on shares of Achillion Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 9th. Zacks Investment Research cut shares of Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Finally, Chardan Capital cut their price target on shares of Achillion Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating on the stock in a report on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the stock. Achillion Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $5.29.
Shares of Achillion Pharmaceuticals (ACHN) opened at $3.69 on Wednesday. Achillion Pharmaceuticals has a fifty-two week low of $3.15 and a fifty-two week high of $5.66.
Institutional investors have recently modified their holdings of the stock. Cambridge Investment Research Advisors Inc. lifted its position in Achillion Pharmaceuticals by 3.6% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 23,130 shares of the biopharmaceutical company’s stock valued at $106,000 after purchasing an additional 800 shares during the period. SG Americas Securities LLC lifted its position in Achillion Pharmaceuticals by 18.6% during the second quarter. SG Americas Securities LLC now owns 26,429 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 4,144 shares during the period. TradeLink Capital LLC bought a new position in Achillion Pharmaceuticals during the second quarter valued at approximately $132,000. Legal & General Group Plc lifted its position in Achillion Pharmaceuticals by 53.8% during the second quarter. Legal & General Group Plc now owns 42,900 shares of the biopharmaceutical company’s stock valued at $196,000 after purchasing an additional 15,000 shares during the period. Finally, UBS Asset Management Americas Inc. lifted its position in Achillion Pharmaceuticals by 83.8% during the first quarter. UBS Asset Management Americas Inc. now owns 53,669 shares of the biopharmaceutical company’s stock valued at $226,000 after purchasing an additional 24,471 shares during the period. Institutional investors own 74.81% of the company’s stock.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.